Home Cart 0 Sign in  
X

[ CAS No. 169447-70-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 169447-70-5
Chemical Structure| 169447-70-5
Chemical Structure| 169447-70-5
Structure of 169447-70-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 169447-70-5 ]

Related Doc. of [ 169447-70-5 ]

Alternatived Products of [ 169447-70-5 ]

Product Details of [ 169447-70-5 ]

CAS No. :169447-70-5 MDL No. :MFCD01862121
Formula : C10H20N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :DATRVIMZZZVHMP-QMMMGPOBSA-N
M.W : 200.28 Pubchem ID :10081508
Synonyms :

Calculated chemistry of [ 169447-70-5 ]

Physicochemical Properties

Num. heavy atoms : 14
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.9
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 63.31
TPSA : 41.57 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.89 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.57
Log Po/w (XLOGP3) : 0.89
Log Po/w (WLOGP) : 0.45
Log Po/w (MLOGP) : 0.86
Log Po/w (SILICOS-IT) : 0.6
Consensus Log Po/w : 1.08

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.44
Solubility : 7.2 mg/ml ; 0.0359 mol/l
Class : Very soluble
Log S (Ali) : -1.35
Solubility : 8.99 mg/ml ; 0.0449 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.44
Solubility : 7.29 mg/ml ; 0.0364 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.62

Safety of [ 169447-70-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 169447-70-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 169447-70-5 ]
  • Downstream synthetic route of [ 169447-70-5 ]

[ 169447-70-5 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 24424-99-5 ]
  • [ 169447-70-5 ]
YieldReaction ConditionsOperation in experiment
93%
Stage #1: With n-butyllithium In tetrahydrofuran at 20℃; for 0.5 h;
Stage #2: With tert-butyldimethylsilyl chloride In tetrahydrofuran for 1 h;
Stage #3: for 1 h;
A solution of (S)-2-methyl piperazine (2 g, 20 mmol) in THF (200 ml_) was mixed with nBuLi (25 ml_, 1.6 M in hexanes, 40 mmol) at rt. The solution was stirred for 30 min before TBDMSCI (3.04 g, 20 mmol) was added. The mixture was stirred for an additional hour and (Boc)2O (5.2 g, 24 mmol) was added to the solution. The resulting mixture was stirred for another hour and diluted with H2O (50 ml_). The organic layer was separated, washed with brine (50 mL), dried over Na2SO4 and concentrated EPO <DP n="38"/>under vacuum. Flash chromatography on silica (5percent MeOH / 2percent NH4OH / 93percent CH2CI2) then provided the title compound as a yellow oil (3.7 g, 93percent). LC/MS: m/z, 201 (M+H); 1HNMR (CDCI3) δ 1.26 (3H, d), 1.49 (9H, s), 2.1 (1 H, s), 2.7 (1 H, m), 2.85 (1 H, m), 3.0 (3H, m), 3.8 (1 H, m), 4.2 (1 H, m).
Reference: [1] Patent: WO2006/55553, 2006, A2, . Location in patent: Page/Page column 36; 37
[2] Journal of Organic Chemistry, 1995, vol. 60, # 13, p. 4177 - 4183
  • 2
  • [ 859517-91-2 ]
  • [ 169447-70-5 ]
YieldReaction ConditionsOperation in experiment
87% With hydrogen In methanol Intermediate 126: 2-(S)-Methyl-piperazine-1-carboxylic acid tert-butyl ester: To the solution of (S)- (+)-2-methyl-piperazine (2.0 g) in methylene chloride (15 mL) at 0°C was added benzylchloroformate (3.0 mL) dropwise. The mixture was stirred at 0°C for one hour then at room temperature for 2 hours, cooled to 0 °C. Diisopropylethylamine (4.5 mL) was added and followed by (Boc) 20 (4.8 g). The mixture was stirred at room temperature overnight then the solvent was removed by rotary evaporation. The residue was dissolved in EtOAc, washed with water, brine, dried over Na2S04, chromatographed on silica gel (EtOAc: hexane = 1 : 9) to give an oily intermediate (4.2 g) in 62percent yield. Hydrogenation with Pd-C (10percent) in methanol gave the title product (2.17 g) in 87percent yield. LC-MS showed the product had the expected M+H+ of 201.'H NMR (Varian 300 MHz, CDC13, shifts relative to the solvent peak at 7.24 ppm) 8 4.2 (s, br, 1H) 3.8 (m, 1H) 3.0 (m, 4H) 2.7 (m, 2H) 1.4 (s, 9H) 1.2 (d, 3H).
Reference: [1] Patent: WO2005/66139, 2005, A2, . Location in patent: Page/Page column 134
  • 3
  • [ 169447-69-2 ]
  • [ 169447-70-5 ]
Reference: [1] Journal of Organic Chemistry, 1995, vol. 60, # 13, p. 4177 - 4183
[2] Synthetic Communications, 2004, vol. 34, # 22, p. 4111 - 4118
[3] Patent: US5736539, 1998, A,
  • 4
  • [ 24424-99-5 ]
  • [ 74879-18-8 ]
  • [ 169447-70-5 ]
YieldReaction ConditionsOperation in experiment
19%
Stage #1: With n-butyllithium In tetrahydrofuran at 20℃; for 0.5 h;
Stage #2: With chloro-trimethyl-silane In tetrahydrofuran for 1 h;
Stage #3: at 20℃; for 1 h;
A solution of (S)-2-methylpiperazine (3.0 g, 30 mmol) in THF (300 mL) was added n- BuLi (2.4M, 25 mL, 60 mmol) dropwisely at room temperature. After the solution was stirred at room temperature for 30 min, TBSC1(4.5 g, 30 mmol) was added to the solution. The mixture was stirred for 1 hour and (Boc)20 (7.8 g, 36 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 1 hour and quenched with H20 (30 mL). The mixture was concentrated and then diluted with EA (300 mL), washed with brine (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica weight: 20 g, eluted with EtOAc/MeOH 10: 1, Et3N 5percent) to give the title compound (1.15 g, 19percent) as oil.
Reference: [1] Patent: WO2014/206344, 2014, A1, . Location in patent: Page/Page column 82; 83
  • 5
  • [ 888973-02-2 ]
  • [ 169447-70-5 ]
Reference: [1] Patent: WO2006/56752, 2006, A1, . Location in patent: Page/Page column 90
[2] Patent: US2008/255150, 2008, A1, . Location in patent: Page/Page column 14
  • 6
  • [ 132871-12-6 ]
  • [ 169447-70-5 ]
Reference: [1] Synthetic Communications, 2004, vol. 34, # 22, p. 4111 - 4118
[2] Journal of Organic Chemistry, 1995, vol. 60, # 13, p. 4177 - 4183
  • 7
  • [ 170033-57-5 ]
  • [ 169447-70-5 ]
Reference: [1] Journal of Organic Chemistry, 1995, vol. 60, # 13, p. 4177 - 4183
  • 8
  • [ 170033-54-2 ]
  • [ 169447-70-5 ]
Reference: [1] Journal of Organic Chemistry, 1995, vol. 60, # 13, p. 4177 - 4183
  • 9
  • [ 118375-95-4 ]
  • [ 169447-70-5 ]
Reference: [1] Synthetic Communications, 2004, vol. 34, # 22, p. 4111 - 4118
  • 10
  • [ 132871-10-4 ]
  • [ 169447-70-5 ]
Reference: [1] Synthetic Communications, 2004, vol. 34, # 22, p. 4111 - 4118
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 169447-70-5 ]

Amides

Chemical Structure| 960283-58-3

[ 960283-58-3 ]

(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride

Similarity: 0.98

Chemical Structure| 1017606-58-4

[ 1017606-58-4 ]

(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate

Similarity: 0.98

Chemical Structure| 674792-07-5

[ 674792-07-5 ]

tert-Butyl 2,2-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 259808-67-8

[ 259808-67-8 ]

tert-Butyl 3,3-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 2061980-49-0

[ 2061980-49-0 ]

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride

Similarity: 0.96

Related Parent Nucleus of
[ 169447-70-5 ]

Aliphatic Heterocycles

Chemical Structure| 960283-58-3

[ 960283-58-3 ]

(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride

Similarity: 0.98

Chemical Structure| 1017606-58-4

[ 1017606-58-4 ]

(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate

Similarity: 0.98

Chemical Structure| 674792-07-5

[ 674792-07-5 ]

tert-Butyl 2,2-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 259808-67-8

[ 259808-67-8 ]

tert-Butyl 3,3-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 2061980-49-0

[ 2061980-49-0 ]

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride

Similarity: 0.96

Piperazines

Chemical Structure| 960283-58-3

[ 960283-58-3 ]

(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride

Similarity: 0.98

Chemical Structure| 1017606-58-4

[ 1017606-58-4 ]

(S)-tert-Butyl 4-(2-aminopropyl)piperazine-1-carboxylate

Similarity: 0.98

Chemical Structure| 674792-07-5

[ 674792-07-5 ]

tert-Butyl 2,2-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 259808-67-8

[ 259808-67-8 ]

tert-Butyl 3,3-dimethylpiperazine-1-carboxylate

Similarity: 0.96

Chemical Structure| 2061980-49-0

[ 2061980-49-0 ]

tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride

Similarity: 0.96